MELIX
Price
$18.45
Change
-$0.34 (-1.81%)
Updated
Jul 2 closing price
Net Assets
96.52M
VEMIX
Price
$37.17
Change
-$0.17 (-0.46%)
Updated
Jul 2 closing price
Net Assets
162.82B
Interact to see
Advertisement

MELIX vs VEMIX

MELIX vs VEMIX Comparison Chart in %
View a ticker or compare two or three
VS
MELIX vs. VEMIX commentary
Jul 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MELIX is a Hold and VEMIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VEMIX has more cash in the bank: 163B vs. MELIX (96.5M). VEMIX pays higher dividends than MELIX: VEMIX (2.31) vs MELIX (0.00). MELIX was incepted earlier than VEMIX: MELIX (15 years) vs VEMIX (26 years). MELIX (1.30) is less costly to investors than VEMIX (0.06). MELIX is a more actively managed with annual turnover of: 59.00 vs. VEMIX (6.00). MELIX has a lower initial minimum investment than VEMIX: MELIX (1000000) vs VEMIX (5000000). VEMIX annual gain was more profitable for investors over the last year : 20.29 vs. MELIX (13.33). VEMIX return over 5 years is better than : 21.53 vs. MELIX (-13.09).
MELIXVEMIXMELIX / VEMIX
Total Expense Ratio0.990.061,650%
Annual Report Gross Expense Ratio1.300.062,167%
Fund Existence15 years26 years-
Gain YTD10.6129.666110%
Front LoadN/AN/A-
Min. Initial Investment1000000500000020%
Min. Initial Investment IRAN/AN/A-
Net Assets96.5M163B0%
Annual Yield % from dividends0.002.31-
Returns for 1 year13.3320.2966%
Returns for 3 years31.0452.8059%
Returns for 5 years-13.0921.53-61%
Returns for 10 years82.4997.8084%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DSFRX40.630.07
+0.17%
Domini Impact Equity Y
SSVIX27.41-0.16
-0.58%
Columbia Select Small Cap Value Inst2
RVVHX11.73-0.08
-0.68%
Royce Small-Cap Value Investment
MFEJX193.29-1.40
-0.72%
MFS Growth R4
FSGAX48.48-0.67
-1.36%
Franklin Small-Mid Cap Growth Adv